MedPath

Kyoto Drug Discovery's KUS121 Investigated for Acute Central Retinal Artery Occlusion

• Kyoto Drug Discovery & Development is sponsoring a study on KUS121 for acute non-arteritic central retinal artery occlusion (CRAO). • The GION study evaluates the efficacy and safety of intravitreal KUS121 injections at high and low doses. • The trial includes a sham procedure as a control, aiming to address the lack of evidence-based therapy for CRAO. • The study is actively recruiting participants to assess KUS121's potential in preventing permanent vision loss from CRAO.

An ophthalmologic emergency, central retinal artery occlusion (CRAO) leads to severe and permanent vision loss, and currently lacks any evidence-based therapy. Kyoto Drug Discovery & Development Co., Ltd. is sponsoring a study to evaluate the efficacy and safety of KUS121 intravitreal (IVT) injection in participants with acute non-arteritic CRAO.
The GION study is designed to assess KUS121, with participants receiving either a high dose of KUS121, a low dose of KUS121, or undergoing a sham procedure. The study aims to determine if KUS121 can offer a viable treatment option for this condition.

Study Details

The study focuses on individuals diagnosed with central retinal artery occlusion. Participants will be administered either a high dose of KUS121, a low dose of KUS121, or will undergo a sham procedure. The primary objective is to evaluate the impact of KUS121 on visual outcomes and safety profiles in patients with acute non-arteritic CRAO.
With no established effective treatment for CRAO, this study could provide critical insights into a potential therapeutic intervention. The outcomes of the GION study are anticipated to inform future clinical strategies for managing acute non-arteritic CRAO and preventing permanent vision loss.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Intravenous Urokinase vs Best Medicine Treatment for Acute Ischemic Stroke: A Comparative Study

A recent study compared the efficacy and safety of intravenous urokinase (UK) with guideline-based best medicine treatment for acute ischemic stroke patients. Conducted across 25 hospitals in China, the TRUST trial aimed to assess functional outcomes, with a focus on patients treated within 6 hours of symptom onset. The study found that UK treatment could potentially offer better functional outcomes, though it also highlighted the importance of careful patient selection due to the risk of symptomatic intracranial hemorrhage.

Aurion Biotech's AURN001 Shows Promise in Phase 1/2 Trial for Corneal Edema

Aurion Biotech's AURN001, an allogeneic cell therapy, demonstrated statistically significant improvement in visual acuity in patients with corneal edema in a Phase 1/2 trial.
The high-dose AURN001 arm showed that 50% of patients achieved a ≥15-letter improvement in best-corrected visual acuity (BCVA) at 6 months, compared to 14.3% in the Y-27632-only arm.

Cysteamine Ophthalmic Solution Shows Promise in Japanese Cystinosis Patients

A Phase III study in Japan evaluated cysteamine hydrochloride 0.55% ophthalmic solution for treating corneal cystine crystals in cystinosis patients.
The study showed a decrease in corneal crystal density and improvement in photophobia, suggesting potential efficacy in Japanese patients.

Kiora Pharmaceuticals Receives IND Approval for KIO-301 Phase 2 Trial in Retinitis Pigmentosa

Kiora Pharmaceuticals has received regulatory approval to commence the ABACUS-2 Phase 2 clinical trial of KIO-301 for retinitis pigmentosa.
The ABACUS-2 trial will enroll 36 patients across five Australian centers, evaluating KIO-301 at two dose levels (50 and 100 micrograms) administered intravitreally.

OKYO Pharma Doses First Subject in Phase II Trial of OK-101 for Neuropathic Corneal Pain

OKYO Pharma has dosed the first subject in its Phase II clinical trial of OK-101 for neuropathic corneal pain (NCP).
The trial is a double-masked, randomized, placebo-controlled study involving 48 patients diagnosed with NCP, confirmed via confocal microscopy.

NT-501 Encapsulated Cell Therapy Shows Promise in Glaucoma Neuroprotection

Phase II study shows NT-501 implant is well-tolerated in primary open-angle glaucoma patients, with no severe adverse events reported.
The therapy maintains intraocular pressure and supports retinal health, crucial for glaucoma management, over a 24-month period.

Dazdotuftide Eye Drops Show Promise in Non-Infectious Uveitis Treatment

Dazdotuftide (TRS01) eye drops demonstrate a favorable safety profile, suggesting potential as a first-line treatment for non-infectious anterior uveitis.
In a Phase 3 trial, TRS01 showed non-inferiority to prednisolone in reducing ocular pain and anterior chamber flare, with fewer IOP elevation risks.

SeaStar Medical's AKI Trial Gains Momentum with Stanford Enrollment and Milestone Achievement

SeaStar Medical's NEUTRALIZE-AKI trial has reached 52 enrolled subjects, with Stanford Medicine now actively participating as an enrollment site.
The pivotal trial assesses the Selective Cytopheretic Device (SCD) in adults with acute kidney injury (AKI) undergoing continuous kidney replacement therapy (CKRT).

Dextenza Insert Shows Strong Efficacy in Allergic Conjunctivitis Phase 3 Trial

A Phase 3 trial of the dexamethasone intracanalicular insert (Dextenza) met its primary endpoint, significantly reducing ocular itching associated with allergic conjunctivitis.
The study demonstrated statistically significant improvements in conjunctival redness and other secondary endpoints, indicating broad relief from allergic conjunctivitis symptoms.

IO/TKI Doublets Emerge as Standard of Care in Non-Clear Cell Renal Cell Carcinoma

Phase 2 trials show that IO/TKI combinations, like lenvatinib plus pembrolizumab, demonstrate efficacy in non-clear cell renal cell carcinoma (non-ccRCC) with manageable safety profiles.
KEYNOTE-B61 trial reported a 51% objective response rate (ORR) in non-ccRCC patients treated with lenvatinib and pembrolizumab, supporting NCCN guideline recommendations.

Reference News

[1]
A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central ...
clinicaltrials.llu.edu · Nov 13, 2024

GION study evaluates KUS121 intravitreal injection efficacy and safety in acute non-arteritic CRAO. Interventions includ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy